Clinical Trials Logo

Clinical Trial Summary

RATIONALE: High-grade squamous intraepithelial lesions of the skin near the anus are caused by the human papillomavirus (HPV). Antiviral drugs,, such as cidofovir, act against viruses and may stop these lesions from becoming cancer.

PURPOSE: This phase II trial is studying the side effects and how well topical cidofovir works in treating HIV-infected patients with high-grade squamous intraepithelial lesions of the skin near the anus.


Clinical Trial Description

OBJECTIVES:

Primary

- To evaluate the safety and tolerability of topical cidofovir in HIV-infected patients with perianal high-grade squamous intraepithelial lesions (HSIL).

- To estimate the regression rate of perianal HSIL in patients treated with this regimen.

Secondary

- To determine the human papilloma virus (HPV) DNA types and HPV strain variants present in perianal HSIL and normal perianal tissue.

- To determine if clinical regression of perianal HSIL is associated with clearance of HPV DNA.

- To identify the HPV DNA types present in the anus and cervix and compare them with the HPV DNA present in the perianus in order to determine if the HPV types associated with the perianal lesions are the same as those infecting the anus and cervix.

- To determine if there are abnormally methylated genes in perianal HSIL compared with normal perianal tissue and if these genes are the same or different from those that have been previously identified in anal and cervical dysplasia.

- To determine whether methylated genes are changed after treatment with cidofovir.

- To characterize differences in gene expression in perianal HSIL compared with normal perianal tissue.

- To examine changes in gene expression in perianal HSIL after exposure to cidofovir using RNA microarray analysis and confirm results with real-time polymerase chain reaction.

- To correlate pretreatment CD4 count, viral load, lesion size, methylation pattern, and/or HPV type and strain with the clinical efficacy of topical cidofovir.

OUTLINE: This is a multicenter study.

Patients apply topical cidofovir to the perianus once daily on days 1-5. Patients undergo punch biopsy of pretreatment lesional biopsy sites on day 14. Beginning 2-4 weeks after biopsy, patients receive course 2 of cidofovir therapy. Subsequent treatment repeats every 14 days for up to 6 courses* in the absence of disease progression or unacceptable toxicity.

NOTE: *Patients receive a total of 6 courses of study therapy.

Patients undergo collection of tumor and normal tissue for histopathological and molecular correlative studies. Punch biopsies are obtained at baseline, after the first course of therapy, and at 6 weeks after completion of therapy. Tissue samples are examined for histopathology, human papilloma virus (HPV)DNA typing, DNA methylation, and gene expression (via RNA microarray analysis and polymerase chain reaction).

After completion of study therapy, patients are followed at 6 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00550589
Study type Interventional
Source AIDS Malignancy Consortium
Contact
Status Completed
Phase Phase 2
Start date September 2007
Completion date February 2010

See also
  Status Clinical Trial Phase
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Completed NCT00653146 - The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia N/A
Terminated NCT00629577 - Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples Phase 1
Completed NCT00103246 - Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides Phase 1
Completed NCT00066430 - Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Phase 1
Completed NCT00522197 - ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia Phase 2
Completed NCT00003384 - Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer N/A
Terminated NCT02574442 - Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer
Completed NCT00719563 - American Ginseng in Treating Patients With Fatigue Caused by Cancer Phase 3
Terminated NCT00899951 - Studying Fentanyl in Patients With Cancer N/A
Terminated NCT00611650 - Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia Phase 2
Completed NCT00873288 - Activating Collaborative CIS Support Via Targeted Provider Mailing N/A
Completed NCT00462813 - Diindolylmethane in Treating Patients With Abnormal Cervical Cells Phase 3
Completed NCT00006348 - Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Phase 3
Completed NCT00666731 - Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition
Completed NCT00685568 - Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis Phase 1
Terminated NCT00942422 - Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma Phase 2
Completed NCT00788164 - Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia Phase 1
Completed NCT00513526 - Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection Phase 2